These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37580251)

  • 1. [Ten-year changes in clinical characteristics and antiviral treatment patterns of chronic hepatitis B in China: a CR-HepB-based real-world study].
    Xu XQ; Wang H; Shan S; You H; Nan YM; Xu XY; Duan ZP; Wei L; Hou JL; Zhuang H; Jia JD; Kong YY;
    Zhonghua Gan Zang Bing Za Zhi; 2023 Jul; 31(7):698-704. PubMed ID: 37580251
    [No Abstract]   [Full Text] [Related]  

  • 2. Sustained viral response and relapse after discontinuation of oral antiviral drugs in HBeAg-positive patients with chronic hepatitis B infection.
    Sun F; Li Z; Hu L; Deng W; Jiang T; Wang S; Bi X; Lu H; Yang L; Lin Y; Zeng Z; Shen G; Liu R; Chang M; Wu S; Gao Y; Hao H; Xu M; Chen X; Zhang L; Lu Y; Dong J; Xie Y; Li M
    Front Immunol; 2022; 13():1082091. PubMed ID: 36505492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analysis and significance of HBV DNA below the lower detection limit of HBV RNA levels after long-term NAs antiviral therapy in patients with hepatitis B virus cirrhosis].
    Wang CY; Cao Y; Feng YM; Li J; Jiang B; Zhang Y; Wen J; Zhu YJ; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2022 Jul; 30(7):758-762. PubMed ID: 36038347
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical Outcomes and Quantitative HBV Surface Antigen Levels in Diverse Chronic Hepatitis B Patients in Canada: A Retrospective Real-World Study of CHB in Canada (REVEAL-CANADA).
    Coffin CS; Haylock-Jacobs S; Doucette K; Ramji A; Ko HH; Wong DK; Elkhashab M; Bailey R; Uhanova J; Minuk G; Tsoi K; Wong A; Ma MM; Tam E; Brahmania M; Nudo C; Zhu J; Lowe CF; Osiowy C; Lethebe BC; Congly SE; Chan EKH; Villasis-Keever A; Sbarigia U; Cooper CL; Fung S
    Viruses; 2022 Nov; 14(12):. PubMed ID: 36560672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients.
    García-López M; Lens S; Pallett LJ; Testoni B; Rodríguez-Tajes S; Mariño Z; Bartres C; García-Pras E; Leonel T; Perpiñán E; Lozano JJ; Rodríguez-Frías F; Koutsoudakis G; Zoulim F; Maini MK; Forns X; Pérez-Del-Pulgar S
    J Hepatol; 2021 May; 74(5):1064-1074. PubMed ID: 33278456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B.
    Wang PC; Wei TY; Tseng TC; Lin HH; Wang CC
    Eur J Gastroenterol Hepatol; 2017 Aug; 29(8):946-950. PubMed ID: 28538267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the change in antiviral therapy indication on identifying significant liver injury among chronic hepatitis B virus infections in the grey zone.
    Ren S; Wang W; Lu J; Wang K; Ma L; Zheng Y; Zheng S; Chen X
    Front Immunol; 2022; 13():1035923. PubMed ID: 36389814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.
    Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
    J Gastroenterol; 2019 Feb; 54(2):182-193. PubMed ID: 30136216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naturally occurring deletion/insertion mutations within HBV whole genome sequences in HBeAg-positive chronic hepatitis B patients are correlated with baseline serum HBsAg and HBeAg levels and might predict a shorter interval to HBeAg loss and seroconversion during antiviral treatment.
    Hao R; Xiang K; Peng Y; Hou J; Sun J; Li Y; Su M; Yan L; Zhuang H; Li T
    Infect Genet Evol; 2015 Jul; 33():261-8. PubMed ID: 25976382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B.
    Song JC; Min BY; Kim JW; Kim JY; Kim YM; Shin CM; Lee SH; Hwang JH; Jeong SH; Kim N; Lee DH
    Korean J Hepatol; 2011 Dec; 17(4):268-73. PubMed ID: 22310791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog.
    Tseng TC; Kao JH
    J Gastroenterol; 2013 Jan; 48(1):13-21. PubMed ID: 23090000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment.
    Seto WK; Liu K; Wong DK; Fung J; Huang FY; Hung IF; Lai CL; Yuen MF
    J Hepatol; 2013 Oct; 59(4):709-16. PubMed ID: 23792029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Demographic characteristics and associated influencing factors in treated patients with chronic hepatitis B with hypoviremia : a single-center retrospective cross-sectional study].
    Li T; Kong Y; Liu YY; Liu TF; Ma AD; Li LQ; Pei ZY; Zhang LY
    Zhonghua Gan Zang Bing Za Zhi; 2023 Jan; 31(1):42-48. PubMed ID: 36948848
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical characteristics of hepatic flare and efficacy of antiviral therapy in pregnant women with chronic hepatitis B virus infection].
    Ding Y; Sheng QJ; Zhang C; Wu YY; Yuan SY; Xia TT; An ZY; Dou XG
    Zhonghua Gan Zang Bing Za Zhi; 2019 Feb; 27(2):106-111. PubMed ID: 30818914
    [No Abstract]   [Full Text] [Related]  

  • 15. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
    Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
    World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients.
    Kim YJ; Kim K; Hwang SH; Kim SS; Lee D; Cheong JY; Cho SW
    Clin Mol Hepatol; 2013 Sep; 19(3):300-4. PubMed ID: 24133668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic hepatitis B genotype E in African migrants: response to nucleos(t)ide treatment in real clinical practice.
    Cuenca-Gómez JÁ; Lozano-Serrano AB; Cabezas-Fernández MT; Soriano-Pérez MJ; Vázquez-Villegas J; Estévez-Escobar M; Cabeza-Barrera I; Salas-Coronas J
    BMC Infect Dis; 2018 Nov; 18(1):568. PubMed ID: 30428845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of intrahepatic total HBV DNA, cccDNA and serum HBsAg level in Chronic Hepatitis B patients with undetectable serum HBV DNA during oral antiviral therapy.
    Li J; Sun X; Fang J; Wang C; Han G; Ren W
    Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):635-643. PubMed ID: 28438570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Add-on pegylated interferon augments hepatitis B surface antigen clearance
    Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
    World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.